Effect of once-daily detemir vs NPH insulin on body weight and metabolic control when added to OADs in type 2 diabetesCatrinoiu, DVeresiu, I ABotnariu, E G
The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in PolandingentaconnectDiabetes Technology & Therapeutics
Grzeszczak, W., Czupryniak, L., Kolasa, K., Sciborski, C., Lomon, I.D., McEwan, P.: The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland...
Raslová, K, Tamer, SC, Clauson, P, Karl, D (2007) Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clinical Drug Investigation 27: pp. 279-285...
Daily NPH insulin in combination with an oral agent may be superior to twice daily insulin in this regard, producing similar improvements in HbA1c but less weight gain and hypoglycemia. We compared changes in HbA1c, weight, BMI and treatment satisfaction (...
Therefore, in this study we compared the effects of detemir on glycemic control, BW and fat mass in the ZDF rat model of T2D with two other basal insulins, NPH and insulin glargine. Diabetic ZDF rats received vehicle, NPH, detemir, or glargine subcutaneously twice daily for four weeks. ...